Treatment options for patients with acute myeloid leukaemia (AML) who relapse following an allogeneic stem cell transplant are limited and most will die of resistant leukaemia. Two drugs, Azacitidine (AZA) and Lenalidomide (LEN), have both been shown to have marked clinical activity in patients with AML who have failed to respond to conventional chemotherapy. Combined treatment with AZA and LEN has never been examined in this important patient population. This study will determine the best tolerated combined dose of AZA and LEN in patients who have relapsed after an allogeneic stem cell transplant.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
|
Chief Investigator: Professor Charles Craddock
|
|
|
Sponsor: University of Birmingham
|
|
|
Funders: Bloodwise (Trials Acceleration Programme) and Celgene
|
|
|
Disease Site: Acute Myeloid Leukaemia and Myelodysplasia
|
|
|
Trial Type: Clinical Trial of an Investigational Medicinal Product
|
|
|
Status: Closed
|
|
|
UKCRN Study ID: N/A
|
|
|
Open to new sites? No
|
|
|
Recruitment start date: 05-Feb-2014
|
|
|
Anticipated Recruitment end date: 31-Dec-2016
|
|
|
CRCTU Trial Management Team: Haematology Team
|
|
|
Trial E-mail Address: VIOLA@trials.bham.ac.uk
|
|